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Background: The dipeptidyl-peptidase-IV (DPP-4) inhibitors, including sitagliptin, are used for the treatment of type
2 diabetes mellitus (T2DM). Adiponectin, an adipocyte-derived circulating protein, has anti-atherosclerotic and
anti-diabetic properties and is effectively elevated in bloodstream by thiazolidinediones, an insulin sensitizer. However,
the effect of sitagliptin treatment on serum adiponectin level in T2DM has not fully elucidated in Japanese T2DM
patients. The aim of the present study was to examine the effect of sitagliptin treatment on serum adiponectin levels
in T2DM subjects.
Methods: Twenty-six consecutive Japanese T2DM outpatients were recruited between April 2011 and March 2013, and
randomized into the control (conventional treatment, n = 10) group and sitagliptin treatment group (n = 16). Serum
adiponectin was measured by enzyme-linked immunosorbent assay.
Results: Indices of glycemic control, such as hemoglobin A1c, glycated albumin, and 1.5-anhydro-D-glucitol, were
significantly improved after the three-month treatment in both the control and sitagliptin groups. Serum adiponectin
level was significantly increased in sitagliptin group from 6.7 ± 0.8 to 7.4 ± 1.0 μg/mL without change of body mass
index (p = 0.034), while serum adiponectin level was not altered in the control group (p = 0.601).
Conclusion: In Japanese T2DM patients, serum adiponectin level was elevated by three-month treatment with sitagliptin
without change of body weight.
Trial registration: UMIN000004721
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Adiponectin is synthesized in adipocytes and secreted
into the bloodstream, where it exhibits anti-diabetic and
anti-atherosclerotic effects [1]. Low circulating adipo-
nectin concentrations impact on the pathogenesis of the
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unless otherwise stated.Patients with type 2 diabetes mellitus (T2DM) are
treated with calorie-restricted diet and exercise therapy, if
needed, plus a variety of glucose-lowering agents. Thiazo-
lidinediones, synthetic peroxisome proliferator-activated
receptor-gamma (PPAR-γ) ligands, are known to increase
serum levels of adiponectin through transcriptional
activation [3,4]. Incretin-based compounds, including
glucagon-like peptide-1 (GLP-1) analogues and dipepti-
dyl peptidase-IV (DPP-4) inhibitors, have been available
for the treatment of diabetes in Japan from 2009.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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mote adiponectin secretion via the protein kinase-A
pathway in 3 T3-L1 adipocytes [5] and to increase cir-
culating adiponectin levels in high fat-fed rats [6]. DPP-
4 inhibitors are the new class of oral glucose-lowering
agents by inhibiting the inactivation of incretin hor-
mones. Sitagliptin is the first agent approved in DPP-4
inhibitors. Among clinical trials investigating the effect
of sitagliptin on glycemic control, circulating adiponec-
tin concentration was assessed in several trials. Inter-
estingly, Derosa G et al demonstrated that combination
therapy with sitagliptin and metformin resulted in the
significant increase of adiponectin at 9 months without
change of body weights in the Italian multicenter, ran-
domized, double-blind, placebo controlled trial [7],
while there was a report indicating no change of adipo-
nectin level by sitagliptin [8]. In Japanese T2DM sub-
jects, the effect of sitagliptin on adiponectin level has
not been fully determined. An observational study
showed that plasma adiponectin level was increased after
12-weeks of sitagliptin treatment in Japanese T2DM sub-
jects [9]. However, the effect of incretin-based therapy on
circulating adiponectin in Japanese T2DM subjects has
not been tested in a randomized controlled trial. The
present randomized controlled study investigated the
effect of sitagliptin treatment, the first available DPP-4
inhibitor in Japan, on serum adiponectin level in Japanese
T2DM subjects, compared to conventional treatment
(sulfonylurea [SU] and/or biguanide drugs).
Methods
Participants
The study (START-J study: Effect of Sitagliptin on
Adiponectin and oxidative stress in Diabetic Patients–
Japan, #UMIN000004721) subjects were consecutive
26 Japanese diabetic outpatients with poor glycemic
control (hemoglobin A1c [HbA1c]; 7.6 ± 0.2%), who
adhered to low-calorie diet and exercise and/or re-
ceived with oral hypoglycemic agents (SU and/or bi-
guanide drugs), and were recruited at Suita Municipal
Hospital from April 2011 to March 2013. We excluded
from the study patients who were treated with pioglit-
azone, which is known to increase serum levels of adi-
ponectin [10], α-glucosidase inhibitors, and/or insulin
injection. Patients with severe renal dysfunction under
peritoneal and/or blood dialysis were also excluded
[11,12]. Patients who received the moderate to high
dose of SU agents (glimepiride ≥2 mg/day, glibencla-
mide ≥1.25 mg/day, or gliclazide ≥40 mg/day), were
excluded to avoid a hypoglycemia after sitagliptin ad-
ministration. The Medical Ethics Committees of Suita
Municipal Hospital and Osaka University approved
the protocol of the study, and a signed informed con-
sent was obtained from each participant.Study protocol
This study was a single-center prospective randomized
controlled trial involving T2DM outpatients. T2DM sub-
jects were randomized into either 3-month conventional
treatment (control group) or 3-month treatment with
sitagliptin (dose: 25 or 50 mg/day, sitagliptin group).
Various parameters were assessed at baseline and after
the three-month treatment. According to the judgment
of attending physician, worsening of glycemic control
(HbA1c ≥8.0%) during the follow-up period was cor-
rected by increasing the dose of test drug or adding an-
other oral glucose-lowering agents; 1) sitagliptin group;
increase the dose of sitagliptin up to 100 mg/day, or add
SU agent (glimepiride up to 3 mg/day or gliclazide up to
40 mg/day) and/or biguanide (metformin up to 500 mg/day
or buformin up to 100 mg/day), 2) control group; add a
SU agent (glimepiride up to 3 mg/day or gliclazide up
to 40 mg/day) and/or biguanide (metformin up to
500 mg/day or buformin up to 100 mg/day) (Figure 1).
The attending physicians also verify glycemic control
by glycoalbumin and 1.5-anhydro-D-glucitol (1.5AG).
The upper limit of SU agents was kept to the recom-
mendation of the Japan Diabetes Society. To avoid
lactic acidosis and to perform clinical trial safely, the
upper limit of biguanides was set up.
An oral glucose tolerance test (OGTT) was performed
under overnight fasting at baseline and three-months.
Under 75-g OGTT, plasma glucose and immunoreactive
insulin (IRI) levels were measured at 0, 30, 60, and
120 min. The homeostasis model assessment of insulin
resistance (HOMA-IR) was calculated by the formula:
HOMA-IR (milliunits per liter ×milligrams per deciliter) =
[(fasting IRI × fasting glucose)/405]. The homeostasis
model assessment of pancreatic β-cell function (HOMA-β)
was calculated by the formula: HOMA-β [(milliunits
per liter)/(milligrams per deciliter)] = [(fasting IRI × 360)/
(fasting glucose − 63)]. The insulinogenic index repre-
sented the ratio of IRI to glucose from 0 to 30 min after
glucose loading. Insulin sensitivity index was calculated
by the formula: 10,000/square root of [(fasting glucose ×
fasting IRI) × (mean glucose ×mean IRI during an OGTT)].
Anthropometry and laboratory tests
Body height, body weight, and waist circumference (WC)
were measured in standing position and body mass index
(BMI) was calculated [=weight (kg)/height (m)2]. WC at
the umbilical level was measured with a non-stretchable
tape in late expiration in standing position. Systolic and
diastolic blood pressures were measured with a standard
mercury sphygmomanometer on the left or right arm in
sitting position after taking a rest for 10 min.
Venous blood samples were collected in the morning
after overnight fast to measure serum creatinine, lipids,
glucose, HbA1c (Japan Diabetes Society [JDS]), glycated
Figure 1 Flowchart of START-J study protocol.
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The value of HbA1c (%) was estimated as the National
Glycohemoglobin Standardization Program (NGSP) equiva-
lent value (%), calculated by the formula HbA1c (%) =
HbA1c (JDS,%) + 0.4%. Low-density lipoprotein-cholesterol
(LDL-C) was calculated using the Friedewald formula
[13]. For the purpose of the present study, serum sam-
ples were immediately stored at –20°C after blood col-
lection. All frozen samples were thawed on ice and
subjected to measurements for adiponectin (Adiponectin
ELISA Kit, Otsuka Pharmaceutical Co., Tokushima, Japan)
[10], high-sensitivity C-reactive protein (hsCRP) (N-Latex
CRP II, Dade Behring Inc, Marburg, Germany), and thio-
barbituric acid reactive substances (TBARS) [10] (Japan
Institute for the Control of Aging, Nikken SEIL Co.,
Shizuoka, Japan).
Statistical analysis
Data are presented as mean ± SEM. Differences in fre-
quencies were examined by the χ2 test. Differences be-
tween groups were examined for statistical significance
using Mann-Whitney U test. In all cases, p values <0.05
were considered statistically significant. All analyses
were performed with the StatView software version 5.0
(HULINKS, Inc. Tokyo, Japan).
Results
Baseline characteristics
Among 29 patients who were informed about the aims
of this clinical trial, 3 patients were withdrawn by the
following reasons: one was emergently hospitalized on
the disturbance of consciousness, one discontinued to
attend the hospital, and one was forgotten to collect
blood sample at baseline. The remaining 26 patientswere randomized into two groups by the envelope
method: sitagliptin (n = 16) and control (n = 10) (Figure 1).
The clinical characteristics at baseline are summarized in
Table 1. WC was significantly smaller in sitagliptin group
than in control group. There were no significant differ-
ences in age (p = 0.16), BMI (p = 0.10), fasting glucose
(p = 0.22), HbA1c (p = 0.40) and duration of diabetes
(p = 0.56) between the two groups at baseline.
Clinical features after three-month treatment
In sitagliptin group, all patients were started with 50 mg of
sitagliptin and maintained with the same doses at the end
of study. In control group, there were no patients whose
medication was increased during the study. Three-month
sitagliptin treatment significantly improved HbA1c, GA,
and 1.5AG, compared to at baseline (Table 1, p < 0.05),
without changes in BMI or WC. However, there were no
significant differences in HbA1c, GA, and 1,5-AG between
control and sitagliptin groups at 3 months. Significant
changes were observed in insulinogenic index and serum
triglyceride at 3 months in control group.
75 g-OGTT at baseline and after three-month treatment
OGTT was performed in 21 subjects of all participants.
Figure 2 shows plasma glucose and IRI levels under 75 g-
OGTT before and after treatment. There were no signifi-
cant changes in the glucose and insulin curves in both
control (n = 9) and sitagliptin groups (n = 12) (Figure 2).
Figure 3 demonstrates changes in serum levels of
TBARS, hsCRP, and adiponectin. At baseline, there were
no significant differences in TBARS between the control
and sitagliptin groups (p = 0.121). Serum levels of hsCRP
and adiponectin tended to be different in two groups,
but such differences were not statistically significant
Table 1 Summary of characteristics of the study population
Control group (n = 10) Sitagliptin group (n = 16)
Baseline Three-month Baseline Three-month
Age, years 56 ± 5 - 63 ± 2 -
Gender (Male/Female) 6/4 - 9/7 -
Body mass index, kg/m2 28.1 ± 1.4 27.4 ± 1.0 24.9 ± 1.2 24.9 ± 1.2
Waist circumference, cm 99.4 ± 2.9 97.2 ± 3.0 88.8 ± 3.4* 89.0 ± 3.2
Duration of DM, (years) 3.8 ± 1.3 - 4.8 ± 1.1 -
Fasting glucose, mg/dL 156 ± 10 141 ± 6 142 ± 6 134 ± 6
Hemoglobin A1c, (%) 7.8 ± 0.4 7.0 ± 0.2¶ 7.5 ± 0.2 6.8 ± 0.2¶
Glycoalbumin, % 18.2 ± 0.8 16.2 ± 0.9¶ 18.9 ± 0.8 16.5 ± 0.6¶
1.5AG, μg/mL 6.4 ± 1.2 9.7 ± 1.9¶ 8.5 ± 1.4 12.9 ± 1.8¶
HOMA-IR, units 5.02 ± 2.1 3.21 ± 0.9 2.0 ± 0.3 1.7 ± 0.3
HOMA-Iβ, units 45.6 ± 12.1 43.3 ± 11.3 29.7 ± 5.7 28.4 ± 5.0
Insulinogenic index 0.11 ± 0.03 0.15 ± 0.04¶ 0.12 ± 0.02 0.14 ± 0.04
Anti-diabetic therapy
Diet and Excise only, n (%) 9 (90%) 0 (0%) 10 (62.5%) 0 (0%)
Sulfonylurea (SU), n (%) 0 (0%) 5 (50%) 0 (0%) 0 (0%)
Biguanide (BG), n (%) 0 (0%) 3 (30%) 4 (25%) 0 (0%)
SU and BG, n (%) 1 (10%) 2 (20%) 2 (12.5%) 0 (10%)
Sitagliptin, only, n (%) - - - 10 (62.5%)
Sitagliptin and BG, n (%) - - - 4 (25%)
Sitagliptin, SU and BG, n (%) - - - 2 (12.5%)
Hypertension, n (%) 5 (50%) - 13 (81%) -
Systolic blood pressure, mmHg 129 ± 3 132 ± 5 145 ± 6 133 ± 3
Diastolic blood pressure, mmHg 78 ± 5 79 ± 3 80 ± 3 76 ± 2
Dyslipidemia, n (%) 4 (40%) - 8 (50%) -
Triglyceride, mg/dL 228 ± 39 185 ± 30¶ 157 ± 26 135 ± 17
HDL-C, mg/dL 51 ± 4 50 ± 4 58 ± 2 57 ± 3
LDL-C, mg/dL 130 ± 12 124 ± 11 119 ± 7 111 ± 7
Medications
ACEI or ARB, n (%) 2 (20%) 9 (56.3%)
CCBs, n (%) 1 (10%) 5 (31.3%)
Statins, n (%) 1 (10%) 4 (25%)
Antiplatelet drugs, n (%) 0 (0%) 2 (12.5%)
Data are mean ± SEM, n (%).
*p < 0.05 vs. control group. ¶p < 0.05 vs. baseline by the same treatment.
HOMA-IR, homeostasis model assessment-insulin resistance; HOMA-β, HOMA β cell function; 1.5AG, 1.5-anhydro-D-glucitol, ACEI, angiotensin-converting enzyme
inhibitor; ARB, angiotensin II receptor blocker; CCB, calcium-channel blocker.
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ment showed no significant changes in serum levels of
TBARS and hsCRP relative to the baseline in both groups
(Figure 3). Interestingly, sitagliptin treatment resulted in a
significant increase of serum adiponectin level (6.7 ±
0.8 μg/mL at baseline versus 7.4 ± 1.0 μg/mL at post-
treatment, p = 0.034), but there was no such change in
control group (4.6 ± 0.3 μg/mL at baseline versus 4.9 ±
0.7 μg/mL at post-treatment, p = 0.601) (Figure 3).Discussion
The main finding of this study was the significant increase
in serum adiponectin level in T2DM patients at the end of
three-month sitagliptin therapy without change of body
weight.
Cardiovascular disease (CVD) is the leading cause of
morbidity and mortality in patients with diabetes. Lower-
ing blood glucose level is an important aspect of manage-
ment for T2DM. However, there is still debate whether
Figure 2 Plasma glucose and insulin curves under 75 g-OGTT at baseline and three months. Plasma glucose (A) and serum insulin (B)
under 75-gram oral glucose tolerance test (75 g-OGTT) at baseline (A and B, respectively) and 3 months after treatment (C and D, respectively).
Data are mean ± SEM of 9 patients of the control group and 12 patients of the sitagliptin group.
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can actually reduce cardiovascular events, at least in pa-
tients with advanced T2DM [14,15]. The impact of the in-
tensive glycemic control on cardiovascular complications
is still under debate. The United Kingdom Prospective
Diabetes Study (UKPDS) was the first clinical trial to pro-
vide a key evidence for the importance of intensive
glucose-lowering therapy in individuals with newly diag-
nosed T2DM [16,17]. Actually, insulin- or SU-based in-
tensive glucose-lowering treatment significantly reduced
the risk of major microvascular endpoints [16]. However,
such intensive treatment for T2DM did not reach a statis-
tical significance for reduction of macrovascular CVD
events compared with the conventional treatment [16].Figure 3 Changes in serum TBARS, hsCRP, and adiponectin levels. Ser
sensitivity C-reactive protein (hsCRP) (B), and adiponectin (C). Data are mea
sitagliptin group. NS; not significant.Furthermore, the Action to Control Cardiovascular Risk
in Diabetes (ACCORD) study, the Action in Diabetes and
Vascular Disease (ADVANCE) study, and the Veterans
Affairs Diabetes Trial (VADT) have shown no beneficial
effects of the intensive glucose-lowering treatment on pri-
mary cardiovascular endpoints in T2DM [18-20]. Taken
together, these clinical trials suggest that physicians need
to integrate such pleiotropic effects on cardiovascular dis-
ease to improve the quality of drug-therapy decisions.
Adiponectin possesses numerous physiological prop-
erties such as anti-atherosclerotic, anti-diabetic, and
anti-inflammatory effects [1,2]. Subjects with hypoadi-
ponectinemia tend to develop into cardiovascular events
and diabetes [21,22]. It is therefore believed that theum levels of thiobarbituric acid-reacting substance (TBARS) (A), high-
n ± SEM of 10 subjects of the control group and 16 subjects of the
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provide the protection against atherosclerosis and diabetes.
Activation of PPAR-γ by thiazolidinediones increases circu-
lating adiponectin concentration at the transcriptional level
[3,4]. Importantly, PPAR-γ agonist failed to reduce the
atherosclerotic area in adiponectin-deficient mice under
apolipoprotein E (ApoE) knockout background [23], sug-
gesting that thiazolidinediones protect against atheroscler-
osis partly through its enhancing effect on adiponectin.
Actually, the PROactive ("PROspective pioglitAzone Clinical
Trial In macroVascular Events") study reported that pioglita-
zone, a PPAR-γ agonist, improved cardiovascular outcome
in a high-risk population of T2DM patients [24,25].
Incretin-based therapies, GLP-1 receptor (GLP-1R) ago-
nists and DPP-4 inhibitors, enhance the glucose-dependent
insulin secretion and optimize the management of gly-
cemic control without hypoglycemia and weight gain [26].
DPP-4 inhibitors were clinically introduced in 2006, with
sitagliptin (Glactiv®, Januvia®, Xelevia™, Tesavel®) as the first
agent [27], followed by vildagliptin, saxagliptin, linagliptin,
teneligliptin, alogliptin, and anagliptin. Based on their effi-
cacy (which is not inferior to sulfonylureas), low risk of
hypoglycemia, body-weight neutrality, and mostly once-
daily dosing, DPP-4 inhibitors seem to fulfill the aforemen-
tioned requirements [28]. The beneficial effect of DPP-4
inhibitors on cardiovascular events has not been deter-
mined, however several meta-analysis studies have recently
reported the safety of DPP-4 inhibitors on cardiovascular
events [29-32]. The present study, as a randomized clinical
trial, demonstrated for the first time that short-term sita-
gliptin treatment resulted in a significant increase in serum
adiponectin level in T2DM patients without changes in
BMI and WC, which may be an important finding linked
to the pleiotropic effects of sitagliptin in the prevention of
cardiovascular events. Current result may imply that oral
administration of sitagliptin is an effective and well-tolerated
treatment option for cardiovascular management of T2DM
patients.
Several experimental studies showed that treatment
with a GLP-1 analogue [5,6] or DPP4 inhibitors [33,34]
increased serum adiponectin levels, but such GLP-1
analogue-mediated increase of adiponectin has remained
uncertain in human subjects [35]. Furthermore, the
mechanism for the increase of adiponectin by sitagliptin
has not been clarified. Increase of systemic and/or local
oxidative stress reduces adiponectin production [36] and
thus there was a possibility that sitagliptin increased adi-
ponectin directly or indirectly through the decrease of
oxidative stress in T2DM patients. However, no signifi-
cant change of TBARS was observed in present short-
term sitagliptin treatment (Figure 3A). Reduction of
body weight and visceral fat also result in the elevation
of serum adiponectin level [1,2]. In the present study,
there were no significant changes of BMI and WCbefore and after sitagliptin treatment (Table 1). Effect of
sitagliptin or metformin added to pioglitazone mono-
therapy in T2DM patients was explored in the multicen-
ter, randomized, double-blind clinical trial in Italy [8].
This study was performed during 12 months and clinical
parameters were assessed every 3 months. Plasma adipo-
nectin level was not altered in sitagliptin group, but was
significantly elevated at 12 months in metformin group.
Plasma hsCRP levels were significantly decreased at
12 months in both groups. Pioglitazone has been shown as
a significant enhancer of adiponectin [3,4] and thus
sitagliptin-dependent increase of adiponectin may be
masked by pioglitazone. Similar group also investigated the
effect of the sitagliptin plus metformin combination ther-
apy or metformin monotherapy in Italy [7]. They showed
the significant elevation of adiponectin at 9 and 12 months
in the combination therapy with sitagliptin and metformin
and at 12 months in the metformin monotherapy. Interest-
ingly, significant reduction of body weight was observed at
12 months in both groups, indicating the possibility that
sitagliptin possesses the elevation of circulating adiponectin
prior to weight reduction. Present study also showed
the sitagliptin-dependent increase of adiponectin without
change of BMI. Recently, the 6 months treatment with vil-
dagliptin, one of DPP4 inhibitors, has been shown to de-
crease body weight, WC, and fat mass, and to increase
adiponectin level [37], suggesting the possibility that long-
term sitagliptin treatment may reduce visceral fat mass and
elevate serum adiponectin level. Further experimental and
larger scale clinical studies including long-term follow-up
studies are required to determine the mechanism of the
beneficial effects of sitagliptin on serum adiponectin.
The present study demonstrated that three-month sita-
gliptin treatment increased circulating adiponectin levels
in T2DM patients without changes in BMI, although sev-
eral study limitations have arisen below. The previous and
present findings may provide the possibility that sitagliptin
potentially possesses pleiotropic and protective effects
against atherosclerotic cardiovascular events.
Study limitations
The present study has several limitations. The study popu-
lation was small and the number of sitagliptin group was
larger than that of the control group, although subjects
were randomized by the envelope method. Selection of
medicine was left on the attending physician. WC at base-
line was significantly larger in control group than in sita-
gliptin group. There were several imbalances in age, BMI,
blood pressure, lipid profile, and medications between
control and sitagliptin groups. In addition, the treatment
period was limited to three-months only. Collectively,
crossover clinical trials and/or long-term/large-scale stud-
ies are desired to confirm the effects of sitagliptin on
serum adiponectin level and cardiovascular outcome.
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